THX Pharma Société Anonyme (EPA:ALTHX)

Market Cap	28.01M
Revenue (ttm)	876.13K
Net Income (ttm)	-2.94M
Shares Out	13.80M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,955
Average Volume	68,811
Open	2.030
Previous Close	2.030
Day's Range	2.020 - 2.050
52-Week Range	0.261 - 3.660
Beta	1.48
RSI	48.48
Earnings Date	Dec 24, 2025

About EPA:ALTHX

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 10
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTHX

Financial Performance

In 2024, EPA:ALTHX's revenue was 2.28 million, an increase of 670.55% compared to the previous year's 296,331. Losses were -1.77 million, -74.15% less than in 2023.